Product Description
Mechanisms of Action: GLP-2 Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: Orphan Drug - Graft vs Host Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 9 Meters Biopharma
Company Location: RALEIGH NC 27615
Company CEO: John Temperato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Graft vs Host Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/09/2020 |
News Article |
9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD) |